Efficacy of Adjuvant Interferon‐β Versus Observation for Resected Nail Apparatus Melanoma: A Multicenter Retrospective Study
The Journal of Dermatology · 2026-08 · 53 (8) · 1124-1132
DOI: 10.1111/1346-8138.70375 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Dermatology, online erschienen am 06.07.2026. Verfasst von Takaya Komori und 45 weiteren Autor:innen. Beteiligte Einrichtung: Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Melanoma, Interferon-beta, Skin Neoplasms, Watchful Waiting. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nail apparatus melanoma (NAM) is a biologically and clinically distinct subtype of melanoma; however, the efficacy of adjuvant interferon (IFN) therapy in this population remains unclear. We conducted a multicenter retrospective study to compare adjuvant IFN‐β (adj‐IFN) with observation (OBS) in patients with resected stage IIB, IIC, or III NAM. We analyzed 282 Japanese patients treated at 42 institutions between 2014 and 2024. Recurrence–free survival (RFS) and distant metastasis–free survival (DMFS) were co‐primary outcomes, and overall survival (OS) was a secondary outcome. Survival outcomes were assessed using Kaplan–Meier analyses and Cox multivariable proportional hazards models. To minimize the differences of baseline characteristics between the two groups, propensity score matching (PSM) was applied. In multivariable Cox analyses, adj‐IFN showed improved RFS (HR 0.67, 95% CI 0.45–0.998, p = 0.049), while no statistically significant benefits were observed for DMFS (HR 0.66, 95% CI 0.42–1.01, p = 0.06) or OS (HR 0.85, 95% CI 0.54–1.35, p = 0.50) compared with OBS. After PSM (71 patients per group), survival outcomes were comparable between the two groups, with no statistical significance in RFS (HR 0.71, 95% CI 0.45–1.12, p = 0.14), DMFS (HR 0.73, 95% CI 0.44–1.20, p = 0.22), or OS (HR 1.01, 95% CI 0.58–1.78, p = 0.96). In conclusion, no significant survival advantage of adj‐IFN over observation was demonstrated in the matched cohort. Although a borderline association with improved RFS was observed in the overall cohort, this finding did not translate into consistent benefit across endpoints. Further prospective evidence, including the final results of the randomized phase III trial (JCOG1309, J‐FERON), is required to clarify the clinical role of adj‐IFN in NAM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan.
- Department of Dermatology, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan.
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
ORCID-Profile: Takaya Komori, Eiji Nakano, Yukiko Kiniwa, Sotaro Yamamoto, Shusuke Yoshikawa, Tatsuya Takenouchi, Yoshiyuki Nakamura, Toshihiro Takai, Takamichi Ito, Hiraku Kokubu, Naohito Hatta, Toshihiko Hoashi, Takayuki Suyama, Mamiko Masuzawa, Takuya Miyagawa, Soichiro Kado, Jun Asai, Junji Kato, Taku Maeda, Takeo Maekawa, Ko Kagoyama, Katsuhiko Nishihara, Dai Ogata, Kenjiro Namikawa, Yasuhiro Nakamura, Shigeto Matsushita
Zitieren
APA
Komori, T., Nakano, E., Kiniwa, Y., Mori, S., Yamamoto, S., Kato, H., Yoshikawa, S., Yoshino, K., Aoki, M., Takenouchi, T., Maeda, T., Yoshino, K., Ohe, S., Nakama, K., Ishikawa, H., Nakamura, Y., Takai, T., Ito, T., Kitagawa, H., …, & Matsushita, S. (2026). Efficacy of Adjuvant Interferon‐β Versus Observation for Resected Nail Apparatus Melanoma: A Multicenter Retrospective Study. The Journal of Dermatology, 53(8), 1124-1132. https://doi.org/10.1111/1346-8138.70375
Vancouver
Komori T, Nakano E, Kiniwa Y, Mori S, Yamamoto S, Kato H, et al. Efficacy of Adjuvant Interferon‐β Versus Observation for Resected Nail Apparatus Melanoma: A Multicenter Retrospective Study. The Journal of Dermatology. 2026;53(8):1124-1132. doi:10.1111/1346-8138.70375
BibTeX
@article{Komori2026,
author = {Komori, Takaya and Nakano, Eiji and Kiniwa, Yukiko and Mori, Shoichiro and Yamamoto, Sotaro and Kato, Hiroshi and Yoshikawa, Shusuke and Yoshino, Koji and Aoki, Megumi and Takenouchi, Tatsuya and Maeda, Takuya and Yoshino, Keijun and Ohe, Shuichi and Nakama, Kenta and Ishikawa, Hideyuki and Nakamura, Yoshiyuki and Takai, Toshihiro and Ito, Takamichi and Kitagawa, Hiroshi and Kokubu, Hiraku and Hatta, Naohito and Funakoshi, Takeru and Hoashi, Toshihiko and Suyama, Takayuki and Fujiwara, Susumu and Masuzawa, Mamiko and Uchi, Hiroshi and Miyagawa, Takuya and Kado, Soichiro and Yamamoto, Yuki and Asai, Jun and Kato, Junji and Maeda, Taku and Baba, Natsuki and Kato, Yukihiko and Oashi, Kohei and Maekawa, Takeo and Jinnai, Shunichi and Nishizawa, Aya and Kagoyama, Ko and Otsuka, Atsushi and Nishihara, Katsuhiko and Ogata, Dai and Namikawa, Kenjiro and Nakamura, Yasuhiro and Matsushita, Shigeto},
title = {Efficacy of Adjuvant Interferon‐β Versus Observation for Resected Nail Apparatus Melanoma: A Multicenter Retrospective Study},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {8},
pages = {1124--1132},
doi = {10.1111/1346-8138.70375}
}
EUVIMED